AMAG presents new data from two ferumoxytol stage III trials on IDA at ASH annual meeting AMAG Pharmaceuticals, Inc. today announced that fresh data from two pivotal phase III medical trials were shown at the American Society of Hematology's annual meeting in Atlanta, Georgia. The phase III trials evaluated the usage of ferumoxytol in subjects with iron insufficiency anemia , of the underlying cause of the anemia regardless, who had failed or could not tolerate oral iron treatment sildenafil citrate . New data from an investigator-initiated research analyzing a one gram 15-minute infusion of ferumoxytol are also being shown at ASH; the existing approved dosing of ferumoxytol can be two 510 mg injections, three to eight times apart.
Related StoriesGenetic carrier screening: an interview with Don Hardison, CEO of Good Start GeneticsApplying a top restaurant model to health care communications: an interview with Brandi Robinson, SanofiRE.Function showcases potential technology and innovations in deep learning softwareAMGA emphasized the need for further fine detail on many of the proposed objectives, the necessity to scale back a few of the more aggressive requirements so they are attainable, and the need for using definitions that are consistent with those commonly found in healthcare delivery. Furthermore, AMGA took the chance expressing concern that the timetables involved may not allow enough time for the vendor community to respond appropriately with upgraded products, nor allow eligible specialists enough time to implement and train on the products.